Form 4: CytomX CSO Sells Shares for Tax Obligations

CytomX Therapeutics' Chief Scientific Officer, Marcia Belvin, sold 31,492 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, Inc. (CTMX), reported a sale of common stock.
• The transaction involved the disposition of 31,492 shares of common stock on March 17, 2026.
• The shares were sold at a price of $6.423 per share.
• The sale was conducted solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (RSUs).
• Following this transaction, Marcia Belvin beneficially owns 300,760 shares, which includes 135,833 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, non-discretionary sale to cover tax liabilities associated with RSU vesting, which is common for executives and does not indicate a change in company fundamentals or management's confidence.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that sales of shares by corporate officers to cover tax withholding obligations upon the vesting of restricted stock units are a routine and common occurrence in the industry. These transactions are typically non-discretionary and do not necessarily reflect a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's long-term view.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary sale of shares by an executive to cover tax obligations related to RSU vesting. This type of insider transaction typically does not reflect a change in the company's fundamental outlook or the executive's confidence in the company. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

CytomX Therapeutics, CTMX, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Obligations, Marcia Belvin